Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results
Harrow Licenses Canadian Rights to Apotex for Ophthalmic Products
Harrow Announces New Appointments to its Board of Directors
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%
Harrow Partners with Leading Healthcare Market Access Technology Platforms
Harrow Completes Transfer of the TRIESENCE® New Drug Application
Harrow Announces Third Quarter 2023 Financial Results
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
Harrow Completes Transfer of NDAs and Launches FLAREX®